Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (301)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04854044 | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 12, 2021 | clinicaltrials |
| NCT03008148 | Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM | unknown | Phase 2 / Phase 3 | 288 | Johnpro Biotech, Inc.INDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT04790097 |
| FET-PET Directed Simultaneous In-field Boost for Primary GBM(dualFETboost) |
| completed |
| N/A |
| 17 |
| Prof. Franciszek Lukaszczyk Memorial Oncology CenterOTHER |
| 1 |
| May 6, 2021 |
| clinicaltrials |
| NCT04874506 | MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) | unknown | Phase 2 | 55 | Matrix Biomed, Inc.INDUSTRY | 1 | May 5, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04116138 | Antisecretory Factor in Primary Glioblastoma 1(AFGBM1) | completed | Phase 1 / Phase 2 | 8 | Peter SiesjöOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02903069 | Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer | completed | Phase 1 | 66 | CelgeneINDUSTRY | 3 | Apr 19, 2021 | clinicaltrials |
| NCT03025893 | A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme(STELLAR) | unknown | Phase 2 / Phase 3 | 100 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT04846257 | Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict Recurrence | completed | — | 260 | Egyptian Medical SyndicateOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03419403 | UNITE Study: Understanding New Interventions With GBM ThErapy | terminated | Phase 3 | 40 | AbbVieINDUSTRY | 5 | Apr 14, 2021 | clinicaltrials |
| NCT03980249 | Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells | withdrawn | Early Phase 1 | 0 | West Virginia UniversityOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT03283631 | Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM(INTERCEPT) | terminated | Phase 1 | 2 | Gary Archer Ph.D.OTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT04829097 | Neoadjuvant Temozolomide Combined With Simultaneous IMRT for Treatment of Glioblastoma | unknown | Phase 3 | 80 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT00590681 | Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 62 | University of ChicagoOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02630030 | Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma | completed | Early Phase 1 | 3 | Emory UniversityOTHER | 1 | Mar 26, 2021 | clinicaltrials |
| NCT02678975 | Disulfiram in Recurrent Glioblastoma | completed | Phase 2 / Phase 3 | 88 | Sahlgrenska University HospitalOTHER | 2 | Mar 18, 2021 | clinicaltrials |
| NCT01180816 | Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA | completed | Phase 1 | 21 | Northwell HealthOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT02340156 | Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma | terminated | Phase 2 | 1 | SynerGene Therapeutics, Inc.INDUSTRY | 2 | Mar 3, 2021 | clinicaltrials |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | terminated | Phase 1 | 35 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Mar 2, 2021 | clinicaltrials |
| NCT00400322 | Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection | completed | N/A | 42 | Karolinska InstitutetOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT04772846 | Chloroquine for Glioblastoma. | unknown | Phase 1 / Phase 2 | 60 | Egyptian Medical SyndicateOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT01290939 | Bevacizumab and Lomustine for Recurrent GBM | completed | Phase 3 | 592 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 15, 2021 | clinicaltrials |
| NCT02758366 | Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma | terminated | Phase 2 | 21 | Meyer Children's Hospital IRCCSOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT03258021 | TTFields In GErmany in Routine Clinical Care(TIGER) | unknown | — | 710 | NovoCure Ltd.INDUSTRY | 1 | Jan 28, 2021 | clinicaltrials |
| NCT03615404 | Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma(ATTAC-P) | completed | Phase 1 | 11 | Gary Archer Ph.D.OTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT02904525 | Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model(XENOGBM) | unknown | N/A | 20 | Andreas HottingerOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT03033524 | Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma | completed | Phase 2 | 12 | PharmAbcineINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT04588454 | 18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme(PSMA-GBM) | unknown | N/A | 5 | Radboud University Medical CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT01740258 | Bevacizumab Beyond Progression (BBP)(BBP) | completed | Phase 2 | 68 | Duke UniversityOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT02296476 | A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) | terminated | Phase 2 | 12 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT04725214 | Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma | unknown | Phase 2 | 33 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04717999 | Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma | unknown | N/A | 20 | UWELL BiopharmaINDUSTRY | 0 | Jan 22, 2021 | clinicaltrials |
| NCT04715620 | Niraparib Combined With Radiotherapy in rGBM | unknown | Phase 2 | 30 | Tianjin Huanhu HospitalOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT02209948 | Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma. | completed | Phase 2 | 166 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT04689087 | A Prospective, Open-label, Single-arm Clinical Study | unknown | N/A | 40 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT02337491 | Pembrolizumab +/- Bevacizumab for Recurrent GBM | completed | Phase 2 | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT04674527 | Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma | unknown | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 19, 2020 | clinicaltrials |
| NCT04674579 | Automatic Segmentation MRI Cerebral Glioma | unknown | — | 50 | Assiut UniversityOTHER | 0 | Dec 19, 2020 | clinicaltrials |
| NCT02605746 | Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis | completed | Early Phase 1 | 10 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Dec 11, 2020 | clinicaltrials |
| NCT01905228 | A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm | completed | Phase 1 | 83 | IncuronINDUSTRY | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02207010 | A Phase 0 Study of AZD1775 in Recurrent GBM Patients | completed | Early Phase 1 | 20 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT01473901 | A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 | 38 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 9, 2020 | clinicaltrials |
| NCT01934361 | Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 | 35 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT03603379 | Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas(GBM-LIPO) | completed | Phase 1 | 9 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04583020 | Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT00031083 | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | completed | Phase 1 | 12 | BiogenINDUSTRY | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03619239 | Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma(GBM) | completed | Phase 1 | 15 | Genexine, Inc.INDUSTRY | 1 | Nov 10, 2020 | clinicaltrials |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | terminated | Phase 1 / Phase 2 | 11 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 5, 2020 | clinicaltrials |
Data updated 24 days agoSource updated May 12, 2021source: clinicaltrials